Brazil Gives Medtech More Time to Deal With Technical Dossier Rule
Executive Summary
Anvisa has extended the deadline for companies to prepare technical dossiers for low-risk medical devices and in vitro diagnostics, giving industry more time to deal with the costs and work involved with complying with the new requirement.
You may also be interested in...
Brazil’s ANVISA Globalizes on Class I/II Medtech Regs, Hikes Fees
New medical technology resolutions issued by Brazil’s healthcare products regulatory agency, ANVISA, are designed to help both the regulator and medtech manufacturers, in terms of simplified processes and speed to market.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.
EU CHMP Opinions And MAA Updates
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.